183 related articles for article (PubMed ID: 26506314)
21. Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.
Trotta F; Da Cas R; Rajevic M; Rossi M; Traversa G
BMJ Open; 2015 May; 5(5):e006619. PubMed ID: 26009573
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and safety of tiotropium Respimat in the treatment of chronic obstructive pulmonary disease: systematic review].
Cai HD; Hou J; Lyu YN; Xiong L; Lu MZ; Wu SL
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Aug; 40(8):596-603. PubMed ID: 28810313
[No Abstract] [Full Text] [Related]
23. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
Tashkin DP; Martinez FJ; Rodriguez-Roisin R; Fogarty C; Gotfried M; Denenberg M; Gottschlich G; Donohue JF; Orevillo C; Darken P; St Rose E; Strom S; Fischer T; Golden M; Reisner C
Respir Med; 2016 Nov; 120():16-24. PubMed ID: 27817811
[TBL] [Abstract][Full Text] [Related]
24. Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR
Anzueto A; Calverley PMA; Mueller A; Metzdorf N; Haensel M; Jardim JR; Pizzichini E; Giraldo H; Ramirez-Venegas A; Giugno ER
Arch Bronconeumol (Engl Ed); 2018 Mar; 54(3):140-148. PubMed ID: 29317111
[TBL] [Abstract][Full Text] [Related]
25. Tiotropium Respimat Soft Mist Inhaler versus HandiHaler to improve sleeping oxygen saturation and sleep quality in COPD.
Bouloukaki I; Tzanakis N; Mermigkis C; Giannadaki K; Moniaki V; Mauroudi E; Michelakis S; Schiza SE
Sleep Breath; 2016 May; 20(2):605-12. PubMed ID: 26407963
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of patients' real-world post-dispensing use and storage environments of tiotropium bromide Respimat® soft mist inhaler on its in vitro dose delivery and lung deposition.
Ammari WG; Khalil Mohammad M; Tayyem RF
Pulm Pharmacol Ther; 2019 Oct; 58():101829. PubMed ID: 31352077
[TBL] [Abstract][Full Text] [Related]
27. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.
Ichinose M; Fujimoto T; Fukuchi Y
Respir Med; 2010 Feb; 104(2):228-36. PubMed ID: 19969446
[TBL] [Abstract][Full Text] [Related]
28. Bronchodilator Effect of Tiotropium via Respimat
Ogasawara T; Sakata J; Aoshima Y; Tanaka K; Yano T; Kasamatsu N
Intern Med; 2017 Sep; 56(18):2401-2406. PubMed ID: 28824055
[TBL] [Abstract][Full Text] [Related]
29. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients.
Molimard M; Raherison C; Lignot S; Balestra A; Lamarque S; Chartier A; Droz-Perroteau C; Lassalle R; Moore N; Girodet PO
Eur Respir J; 2017 Feb; 49(2):. PubMed ID: 28182569
[TBL] [Abstract][Full Text] [Related]
30. Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators.
Halpin DM; Kaplan AG; Russell RK
Respir Med; 2017 Jul; 128():28-41. PubMed ID: 28610667
[TBL] [Abstract][Full Text] [Related]
31. In vitro and clinical characterization of the valved holding chamber AeroChamber Plus
Wachtel H; Nagel M; Engel M; El Azzi G; Sharma A; Suggett J
Respir Med; 2018 Apr; 137():181-190. PubMed ID: 29605203
[TBL] [Abstract][Full Text] [Related]
32. In vitro dose comparison of Respimat
Ciciliani AM; Langguth P; Wachtel H
Int J Chron Obstruct Pulmon Dis; 2017; 12():1565-1577. PubMed ID: 28603412
[TBL] [Abstract][Full Text] [Related]
33. Effect of tiotropium on COPD exacerbations: A systematic review.
Halpin DM; Vogelmeier C; Pieper MP; Metzdorf N; Richard F; Anzueto A
Respir Med; 2016 May; 114():1-8. PubMed ID: 27109805
[TBL] [Abstract][Full Text] [Related]
34. Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials.
Hohlfeld JM; Furtwaengler A; Könen-Bergmann M; Wallenstein G; Walter B; Bateman ED
Int J Clin Pract; 2015 Jan; 69(1):72-80. PubMed ID: 25496316
[TBL] [Abstract][Full Text] [Related]
35. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
[TBL] [Abstract][Full Text] [Related]
36. Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD - real-life experience from an observational study.
Jahnz-Różyk K; Szepiel P
Int J Chron Obstruct Pulmon Dis; 2015; 10():613-23. PubMed ID: 25834420
[TBL] [Abstract][Full Text] [Related]
37. Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses.
Tashkin DP; Bateman ED; Jones P; Zubek VB; Metzdorf N; Liu D; Leonard T; Clerisme-Beaty E; Wise RA
Respir Med; 2016 Nov; 120():91-100. PubMed ID: 27817821
[TBL] [Abstract][Full Text] [Related]
38. Tiotropium formulations and safety: a network meta-analysis.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Ther Adv Drug Saf; 2017 Jan; 8(1):17-30. PubMed ID: 28203364
[TBL] [Abstract][Full Text] [Related]
39. In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.
Horhota ST; van Noord JA; Verkleij CB; Bour LJ; Sharma A; Trunk M; Cornelissen PJ
AAPS J; 2015 Jul; 17(4):871-80. PubMed ID: 25794622
[TBL] [Abstract][Full Text] [Related]
40. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
Ferguson GT; Karpel J; Bennett N; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
NPJ Prim Care Respir Med; 2017 Feb; 27(1):7. PubMed ID: 28154373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
